Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 93

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 6
Chunk 93
---
ical
research and development at Cleara Biotech in Utrecht, The Netherlands. As head of translational sciences at Cleara Biotech, he was responsible
for translating research on anti-senescent drugs into pre-clinical development in age-related diseases and late-stage cancer. In May
2021 he re-joined Aeterna Zentaris as Senior Vice-President Non-Clinical Development and Chief Scientific officer. Dr. Teifel holds a
degree in biology and his Ph. D. from the Technical University of Darmstadt, Germany.

  65  

There are no family relationships between any of
the persons named above and no arrangement with any customers, major shareholders, suppliers or others pursuant to which any person above
was selected as a director or executive officer. Each director holds office until the Company’s next annual general meeting or
until a successor is duly elected or appointed.

  Compensation  
 ────────────────

Our directors and executive officers are generally
paid in their home country currency. Unless otherwise indicated, all compensation information included in this document is presented
in U. S. dollars and, to the extent a director or officer has been paid in a currency other than U. S. dollars, the amounts have been converted
from such person’s home country currency to U. S. dollars based on the following annual average exchange rates: for the financial
year ended December 31, 2024: €1.000 = U. S.$1.082 and CAN$1.000 = U. S.$0.741; for the financial year ended December 31, 2022: €1.000
= U. S.$1.053 and CAN$1.000 = U. S.$0.759; for the financial year ended December 31, 2021: €1.000 = U. S.$1.182 and CAN$1.000 = U. S.$0.797.

Compensation of Outside Directors

The compensation paid to members of our Board who
are not our employees (our “ Outside Directors”) is designed to (i) attract and retain the most qualified people to
serve on the Board and its committees, (ii) align the interests of the Outside Directors with those of our shareholders, and (iii) provide
appropriate compensation for the risks and responsibilities related to being an effective Outside Director. This compensation is recommended
to the Board by the Nominating, Governance and Compensation Committee (“NGCC”). The NGCC